VGF (non-acronymic) is a neurosecretory protein initially identified as a nerve growth factor-responsive transcript in sensory neurons. It encodes a precursor protein that undergoes proteolytic cleavage to generate multiple bioactive peptides, including TLQP-62. NERP-1/2. and AQEE-30. implicated in energy homeostasis, pain modulation, and neuroendocrine regulation. VGF-derived peptides are widely expressed in the central and peripheral nervous systems, endocrine cells, and metabolic tissues.
VGF antibodies are essential tools for detecting VGF protein or its processed peptides in research. They enable the investigation of VGF's roles in neuroplasticity, stress response, and metabolic disorders. These antibodies are commonly used in techniques like Western blotting, immunohistochemistry, and ELISA to map VGF expression patterns in brain regions (e.g., hypothalamus, hippocampus) and peripheral tissues.
Studies utilizing VGF antibodies have linked altered VGF levels to depression, schizophrenia, Alzheimer’s disease, and metabolic syndromes. For example, reduced hippocampal VGF correlates with cognitive deficits, while its overexpression in adipose tissue influences insulin sensitivity. Commercially available VGF antibodies often target specific epitopes (e.g., C-terminal regions), but validation via knockout controls is critical due to potential cross-reactivity with structurally similar peptides. Emerging applications include exploring VGF as a biomarker or therapeutic target for neuropsychiatric and metabolic diseases.